Search results
Showing 181 to 195 of 243 results for learning disabilities
Evidence-based recommendations on certolizumab pegol (Cimzia) for treating severe active rheumatoid arthritis in adults who have had a tumour necrosis factor-alpha inhibitor.
Evidence-based recommendations on ixekizumab (Taltz) for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritis in adults.
Fenfluramine for treating seizures associated with Dravet syndrome (TA808)
Evidence-based recommendations on fenfluramine (Fintepla) for treating seizures associated with Dravet syndrome in people aged 2 and older.
Evidence-based recommendations on fremanezumab (Ajovy) for preventing migraine in adults.
This guideline covers how to make shared decision making part of everyday care in all healthcare settings. It promotes ways for healthcare professionals and people using services to work together to make decisions about treatment and care. It includes recommendations on training, communicating risks, benefits and consequences, using decision aids, and how to embed shared decision making in organisational culture and practices.
This guideline covers mental health rehabilitation for adults with complex psychosis. It aims to ensure people can have rehabilitation when they need it and promotes a positive approach to long-term recovery. It includes recommendations on organising rehabilitation services, assessment and care planning, delivering programmes and interventions, and meeting people’s physical healthcare needs.
This guideline covers the planning and management of end of life and palliative care for infants, children and young people (aged 0 to 17 years) with life-limiting conditions. It aims to involve children, young people and their families in decisions about their care, and improve the support that is available to them throughout their lives.
Evidence-based recommendations on galcanezumab (Emgality) for preventing migraine in adults.
Evidence-based recommendations on nusinersen (Spinraza) for treating spinal muscular atrophy in children and adults.
Infliximab and adalimumab for the treatment of Crohn's disease (TA187)
Evidence-based recommendations on infliximab (Remicade) and adalimumab (Humira) for treating severe active Crohn's disease in adults.
Early value assessment (EVA) guidance on digital technologies for delivering multidisciplinary weight-management services.
Early value assessment (EVA) guidance on digital technologies to deliver pulmonary rehabilitation programmes for adults with COPD.
Evidence-based recommendations on golimumab (Simponi) for treating rheumatoid arthritis in adults.
This guideline covers how to communicate the risks and benefits of natural sunlight exposure (specifically, the ultraviolet rays UVA and UVB) to help people understand why they may need to modify their behaviour to reduce their risk of skin cancer and vitamin D deficiency.
Evidence-based recommendations on the bisphosphonates alendronic acid, ibandronic acid, risedronate sodium and zoledronic acid for treating osteoporosis.